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A sensitive and specific screen for Duchenne muscular dystrophy (DMD) has been clinically 
confirmed, but the acceptability of adding DMD to the newborn screening (NBS) program has 
been controversial due to a lack of evidence that early diagnosis improves clinical outcome. With 
promising new gene therapies currently in clinical trials, it is reasonable to consider NBS for 
DMD for early pharmaceutical intervention. It is our objective to assess parents’ attitudes toward 
the acceptability of including DMD, the milder and allelic Becker muscular dystrophy (BMD), 
and spinal muscular atrophy (SMA) in the NBS panel, as well as to determine which factors 
(early diagnosis, family planning, parent-child bonding, anxiety, decision regret, time to prepare) 
are the most influential in parents’ opinions.  
 
Methods: Two cohorts were recruited separately and surveyed about their attitudes toward NBS 
for DMD/BMD/SMA. Expectant parents were recruited with no regard to family history and 
their opinions were compared to those of parents of children with DMD, BMD, or SMA. 
  
Results: Of the 65 parents of children with DMD, BMD, or SMA that were surveyed, 63 (97%) 
supported NBS for DMD/BMD/SMA, either as a mandatory screen or with parental permission. 
Of the 400 expectant parents surveyed, 369 (92.5%) would have their child screened at birth for 
an incurable, life-shortening disease such as DMD/BMD/SMA. Expectant parents, especially 
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those who would choose to have their child screened, viewed the benefits of early diagnosis 
(58.9%) as the most influential factor in their decision. 
 
Conclusions: There is strong support for NBS for DMD/BMD/SMA in both cohorts, which is 
not contingent on further therapeutic development. The consideration of including non-treatable 
diseases in NBS should include consideration of parental opinions on the beneficence of 
screening. Although there is currently no direct medical benefit to early diagnosis in 
DMD/BMD/SMA, parents responded that early diagnosis could have other, less tangible 
benefits. Parental opinions, along with promising clinical trials, make the implementation of an 
optional screen ideal for DMD, BMD, and SMA. 
 
Public Health Importance: NBS is the foremost intersection of genetics and public health. It is 
imperative to involve public opinion when assessing the acceptability of adding a potentially 
controversial disease to a standard panel. 
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1.0  INTRODUCTION 
Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular disease that causes 
progressive proximal muscle weakness, respiratory and cardiac complications, and early death. 
DMD affects approximately 1 in 3500 male births and is the most common form of muscular 
dystrophy. Becker muscular dystrophy (BMD) is an allelic disease with a similar but slower 
progression and affects approximately 1 in 17,500 male births. Spinal muscular atrophy (SMA) 
is an autosomal recessive neurodegenerative disease that is characterized by the degeneration of 
motor neurons in the spinal cord, resulting in progressive muscle weakness and paralysis. SMA 
affects approximately 1 in 6000-10,000 live births.  
There is significant interest in including DMD/BMD/SMA in the newborn screening 
(NBS) program among families affected by these diseases as well as the medical teams that care 
for them. Traditionally, however, NBS is reserved for diseases in which the child clearly benefits 
from early diagnosis and medical intervention, and this improvement in outcome has not been 
reliably shown in DMD, BMD, or SMA. Promising clinical trials involving gene therapy for 
DMD especially have recently rekindled interest in NBS for DMD/BMD/SMA. It is the goal of 
this study to assess the acceptability of NBS for DMD/BMD/SMA among expectant parents and 
parents of children with DMD, BMD, or SMA. This study analyzed parental support for a NBS 
program for DMD/BMD/SMA and compared parental support between expectant parents and 
parents of children who have these diseases.  
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In addition to assessing the acceptability of NBS for DMD/BMD/SMA, this study aims to 
determine what factors influence parents’ opinions on this complex issue. During the 
implementation of an optional NBS for DMD in Wales, Parsons et al. (2002) did a psychosocial 
study into parents’ opinions of screening and found several themes regarding the perceived 
advantages and disadvantages of NBS for DMD. This study used three of the most popular 
advantages (reproductive choice/family planning, time to prepare, and early diagnosis) and three 
of the most popular disadvantages (decision regret, parent-child bonding, and anxiety) to 
determine which factors are the most influential in parents’ opinions toward NBS for 
DMD/BMD/SMA.   
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2.0  HYPOTHESIS AND SPECIFIC AIMS 
2.1.1 Specific Aim 1 
Specific Aim 1: To assess how parents of children with DMD, BMD, or SMA feel about adding 
DMD/BMD/SMA to the NBS program. 
Hypothesis: Parents of children with DMD, BMD, or SMA will be in favor of adding 
DMD/BMD/SMA to the mandatory NBS program because of their previous experience with the 
diagnostic process.  
2.1.2 Specific Aim 2 
Specific Aim 2: To assess how expectant parents feel about adding DMD/BMD/SMA to the 
NBS program. 
Hypothesis: Expectant parents will be in favor of adding DMD/BMD/SMA to the NBS 
program, because of the advantages of early diagnosis.  
2.1.3 Specific Aim 3 
Specific Aim 3: To assess what factors influence expectant parents’ feelings about NBS for 
DMD/BMD/SMA. 
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Hypothesis: The most influential factor in expectant parents’ feelings about NBS for 
DMD/BMD/SMA will be time to prepare, because of the emotional experience of these 
diagnoses.  
2.1.4 Specific Aim 4 
Specific Aim 4: To compare the opinions of expectant parents and parents of children with 
DMD, BMD, or SMA regarding NBS for DMD/BMD/SMA. 
Hypothesis: Parents of children with DMD, BMD, or SMA will be more likely to support 
NBS for DMD/BMD//SMA than expectant parents, because of their personal investment in these 
specific diseases. 
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3.0  BACKGROUND AND SIGNIFICANCE 
3.1 DUCHENNE MUSCULAR DYSTROPHY 
Duchenne muscular dystrophy (DMD) is a neuromuscular disease that causes progressive 
proximal muscle weakness, respiratory and cardiac complications, and eventually, death. DMD 
is the most common muscular dystrophy in children, and affects approximately 1 in 3500 male 
births (Emery, 1991).  
3.1.1 History of DMD 
Duchenne muscular dystrophy is named for C.B. Duchenne de Boulogne, but credit for the first 
clinical description goes to the English physician Charles Bell, who in 1830 described an 18-
year-old man with gradual muscular weakness of the lower extremities and no associated 
findings to suggest a spinal cord disease (Tyler, 2003). In 1851 Edward Meryon gave an 
unequivocal clinical and pathological description of DMD through a paper presented to the 
Royal Medical and Chirurgical Society of London. Although Meryon initially believed the spinal 
cord to be cause of the disease, after performing an autopsy on one of his patients, he was the 
first to suggest that defective nutrition of the muscles was the true cause (Tyler, 2003).  
In 1861, Duchenne described his first patient, seen in 1858, as having “hypertrophic 
paraplegia of infancy of cerebral origin.” However, in 1868, he revised his clinical name to 
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“pseudo-hypertrophic muscular paralysis,” and described 6 principal diagnostic features (as 
quoted in Tyler, 2003) which still apply today: 
1. “Decrease in strength, at the beginning of the disease, usually in the 
muscles of the lower limbs. 
2. Lordosis and spreading of the lower limbs on standing and walking. 
3. Excessive development of volume, during a second stage, either of 
some or all of the weakened muscles.  
4. Progressive course of the disease, during a third stage, with worsening 
of the paralysis and with its generalization if it was limited to the 
inferior members.  
5. Decrease or abolition of electromuscular contractility in an advanced 
stage of the disease. 
6. Absence of fever, sensory disturbance, and impairment of the 
functions of the bladder and intestine during the entire course of the 
disease.” 
William Richard Gowers, an English neurological clinician, was the first to propose that 
there was an inherited component to DMD and described its pattern in 1879 (Tyler, 2003). He 
observed that DMD tends to affect several members of the same family and most commonly 
affects boys, with affected girls seeming to have a milder presentation at a later age (Tyler, 
2003). Regarding family history, Gowers noted that “the disease is never to be heard of on the 
side of the father; always when antecedent cases have occurred, they have been on the side of the 
mother,” – something Gowers referred to as unilateral inheritance (Tyler, 2003). He concluded, 
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“the congenital tendency is exclusively due to the maternal element in the embryo.” (Tyler, 
2003).  
3.1.2 Clinical Features 
Individuals with DMD typically present between the ages of 3-5 years with a delay in the 
achievement of motor milestones, as well as a reduced ability to run and jump (Bushby, 2010). 
Proximal muscle weakness leads to difficulty when rising from the floor, resulting in the 
classical Gowers’ sign. The average age of diagnosis is 5 years old, when there is a distinct 
divergence from their peers in physical ability (Bushby, 1999). Meryon and Duchenne referred 
to the pseudo-hypertrophy associated with DMD, especially in the calf and deltoid muscles, 
which is typically present by ages 5-6 years (Engel, 2004). While still ambulatory, proximal 
muscle weakness causes boys with DMD to have a distinct posture, characterized by thrown 
back shoulders, spinal lordosis, and a wide stance (Pearce, 2000). Tenuous balance leads to a 
wide, abnormal gait, and with no way to recover, affected boys often fall (Doglio, 2011). Uneven 
weakness of agonist and antagonist muscles leads to contractures in approximately 70% of 
affected boys (Engel, 2004).  
As muscle weakness progresses, the course of DMD can be divided into 5 stages: 
presymptomatic, early ambulatory, late ambulatory, early non-ambulatory, and late non-
ambulatory (Bushby, 2010). The transition between ambulatory and non-ambulatory stages 
typically occurs between ages 10-12 years, at which point boys with DMD become wheelchair-
dependent for mobility (Manzur, 2009). In the later stages of disease, boys with DMD are prone 
to progressive kyphoscoliosis, dilated cardiomyopathy (DCM), and respiratory insufficiency. It 
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is not the primary muscle weakness, but complications from respiratory insufficiency and 
especially cardiac failure that most often directly cause death (Eagle, 2002).  
Dystrophin deficiency in cardiac muscle leads to DCM. As the ventricles fill, cardiac 
muscles must stretch, and in the absence of dystrophin, damage occurs (Kaspar, 2009). This 
damage starts an inflammatory response pathway, leading to fibrosis, which makes the cardiac 
muscle less flexible and leads to DCM (Kaspar, 2009).  
There are also well-documented cognitive and psychological problems associated with 
DMD, in approximately 33-50% of cases (Giliberto, 2004; Manzur, 2009; Bushby, 2010). 
Cognitive delays include both overall impaired intelligence and specific learning disabilities, 
most often in verbal areas such as verbal short-term memory and phonological language 
processing (Mehler, 2000; Giliberto, 2004). There is an increased risk for behavioral and 
developmental disorders, including attention-deficit hyperactivity disorder, obsessive-
compulsive disorder, and autism (Bushby, 2010).  
3.1.3 Diagnosis 
Evaluation for DMD is typically considered when abnormal muscle function is observed in a 
male child. This could include using the arms to rise from the floor combined with a wide stance, 
known as Gowers’ sign, or a waddling gait with or without toe walking (Drousiotou, 1998; 
Bushby, 2010). Often, there is an associated frequency of falling, in addition to difficulty running 
or climbing stairs. Other earlier signs of DMD typically seen in retrospection include delayed 
motor milestones such as walking, or a delay in language development (Bushby, 2010).  
The first step for diagnosing DMD is often to test serum creatine kinase (CK) levels. CK 
is an enzyme that is used as a marker for muscle damage (Zellweger, 1975). Although serum CK 
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level is a sensitive indicator of disease, it is not specific for DMD. An elevated CK could 
indicate myocardial infarction, rhabdomyolysis, or other muscular dystrophies (Engel, 2004). 
Typically, the CK levels in patients with DMD are at least ten-fold higher than normal (Zatz, 
1991).  
Once DMD is suspected, confirmation of the diagnosis may include muscle biopsy or 
genetic testing, depending on the clinical situation, availability of genetic testing, and resources 
available to the testing center. Genetic testing is mandatory after a positive muscle biopsy, but a 
muscle biopsy is not always required after a positive genetic test (Bushby, 2010). 
Immunocytochemistry and immunoblotting for dystrophin are used to diagnose DMD by muscle 
biopsy. DMD is distinguished from other milder dystrophinopathies by the complete absence of 
dystrophin expression in muscle in DMD. If dystrophin is present, a muscle biopsy can provide 
information about the amount and size of the dystrophin protein (Bushby, 2010).  
Genetic testing is necessary even after diagnosis of DMD through muscle biopsy because 
the exact mutation type and location provides information about expected prognosis, availability 
of future mutation-specific therapies, and familial implications (Bushby, 2010). Typically, 
deletion/duplication testing is done first, recognizing that between 55-75% of mutations will be 
detected. If no mutation is found through deletion/duplication testing, gene sequencing will 
detect an additional 20-35% of mutations, including smaller deletions and insertions. Knowing 
the exact endpoints and location of a deletion or duplication is key in understanding the effect of 
the mutation on the reading frame of the gene, which is the most important predictive factor in 
phenotypic variability among the dystrophinopathies (Bushby, 2010).  
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3.1.4 Genetics 
DMD follows an X-linked recessive pattern of inheritance. Each child born to a female carrier 
has a 50% chance of inheriting the mutation; male children will be affected with DMD and 
female children will be carriers. Almost all DMD patients are male, but infrequently, the disease 
is manifested in girls with a structurally altered or absent X chromosome (Engel, 2004). Female 
carriers most often do not show symptoms of DMD, but they are at risk for cardiac 
complications later in life, and in rare cases, may have a similar phenotype to affected males 
(Holloway, 2008; Engel, 2004).  
Approximately 2/3 of cases are inherited in this manner (Engel, 2004). The remaining 1/3 
of DMD diagnoses are a result of a de novo mutation in the affected child. This is explained by a 
high spontaneous mutation rate in the dystrophin gene, estimated to be 1 in 10,000 (Emery, 
1991). 
DMD is caused by mutations in the dystrophin gene, located at Xp21 (Hoffman, 1987). 
The dystrophin gene is the largest in the human genome, and makes up 0.1% of the genome 
(Koenig, 1988). It is comprised of 2.4 million base pairs, which encode a 14 thousand base (or 
14 Kb) messenger RNA that comprises 79 exons, and is translated to generate a 3,685 amino 
acid protein (Koenig, 1988). Dystrophin is found in skeletal, cardiac, and smooth muscles, as 
well as the retina, cerebral cortex, lung, and kidney. Small amounts of dystrophin can also be 
detected in the placenta, liver, spleen, and cultured lymphoblastoid cells (Chelly, 1988).  
Dystrophin connects the muscle filament actin to the dystrophin-associated glycoprotein 
complex (DGC). The DGC then connects the muscle fiber membrane (sarcolemma) to the 
extracellular matrix, as shown in Figure 1 (Manzur, 2009; Muntoni, 2003). When functioning 
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correctly, it is therefore thought that dystrophin plays a role in stabilizing the sarcolemma as well 
as protecting it from the damage associated with contraction (Davies, 2006; Manzur, 2009).  
 
 
Figure 1: Localization of Dystrophin (Pichavant, 2011) 
The localization of dystrophin within the muscle fiber. Dystrophin connects the muscle filament actin 
to the dystrophin-associated glycoprotein complex, located in the sarcolemma.  
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Dystrophin protein is made up of 4 domains: an actin-binding domain at the 5’ end, a 
central rod domain, a cysteine-rich domain, and a carboxy (C)-terminal domain at the 3’ end 
(Koenig, 1988). Of these 4 domains, the most critical are the actin-binding and C-terminal 
domains; the central rod domain can be shortened and still retain function (Ervasti, 2007). 
Mutations that shorten this central rod domain without affecting the function of the actin-binding 
or C-terminal domains may cause a milder phenotype, known as Becker muscular dystrophy 
(BMD), discussed below (Engel, 2004). The most influential determining factor of whether a 
mutation preserves the function of these critical regions is whether the mutation results in a shift 
of the transcript reading frame. In large measure, in-frame deletions result in BMD and out-of-
frame deletions result in DMD (Monaco, 1988). However, there are exceptions to this ‘reading 
frame rule.’ In-frame mutations that occur in critical regions of the dystrophin gene such as the 
actin-binding or C-terminal domains can result in a DMD phenotype (Muntoni, 2003; Manzur, 
2009). To some extent, some out-of-frame mutations can be compensated for by alternative 
splicing isoforms, resulting in a BMD phenotype (Muntoni, 2003; Manzur, 2009).  
The most common dystrophin mutations are large deletions, spanning multiple exons. 
Figure 2 illustrates the dystrophin exons. Rectangular blocks represent exons that begin and end 
with whole codons, and blocks with arrows pointing to the right or left represent exons that begin 
or end on the second or third nucleotide. Exons that begin and end with the same codon position 
can be deleted without shifting the reading frame; likewise, if an exon that begins and ends with 
different codon positions is deleted, the reading frame is lost, along with downstream translation. 
Multiple exons can be deleted and still preserve the reading frame, if the beginning of the first 
exon and the end of the last exon coincide with the same relative nucleotide position within the 
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codon. The idea of skipping additional exons to restore the reading frame is the basis of a 
promising new therapy for DMD, discussed in more detail below.  
 
 
Figure 2: Dystrophin Exons (Bellayou, 2009) 
Dystrophin exons, numbered 1-79. Rectangular pieces represent exons that begin and end at codon 
boundaries. Arrows pointing to the right or left represent exons that end on the second and third positions of 
the codon, respectively. 
 
There are four full-length and four truncated transcripts from the dystrophin gene; each 
transcript has a different promotor (Engel, 2004). Each full-length dystrophin isoform is cell-type 
specific, and includes isoforms for muscle cells, cortical cells, Purkinje cells, and lymphoid cells. 
The four truncated variants of dystrophin have intronic promotors, and are named for their 
estimated molecular masses: Dp260, Dp140, Dp116, and Dp71 (Engel, 2004). Different 
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deletions in the dystrophin gene result in the interruption of different dystrophin isoforms, and 
this may contribute to the clinical variability within both DMD and BMD.  
3.1.5 Management 
There is no cure for DMD; current management for boys with DMD provides prophylactic and 
symptomatic treatment and involves a team of specialists, including (but not limited to) 
neurologists, rehabilitation specialists, cardiologists, pulmonologists, pediatricians, orthopedic 
surgeons, and primary care physicians (Bushby, 2010). Principle interventions available can be 
broken down into the following categories: neuromuscular, orthopedic, rehabilitation, 
pulmonary, cardiac, GI/nutrition/speech, and psychosocial. 
3.1.5.1 Neuromuscular Interventions 
Neuromuscular management and therapies primarily revolve around the initiation and 
timing of glucocorticoids, a type of corticosteroid. Currently, glucocorticoids are the only 
medication available to slow the decline in muscle strength and function in DMD (Bushby, 
2010). Glucocorticoids prolong ambulation and reduce the risk for progressive scoliosis as well 
as stabilize pulmonary function variables after ambulation is lost (Yilmaz, 2004; Manzur, 2009). 
The two most widely used glucocorticoids are prednisone and deflazacort.  
Timing the initiation of glucocorticoids is an individual decision, and should take into 
account age, current functional state, and risk factors for complications (Bushby, 2010). Side 
effects of early steroid treatment include excessive weight gain and behavioral abnormalities 
(Merlini, 2003; Manzur, 2008). It is the current recommendation that glucocorticoids should be 
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initiated once the gain in motor milestones has plateaued, but before motor function begins to 
decline (Bushby, 2010).  
Other supplements have been used, including coenzyme Q10, carnitine, certain amino 
acids, and anti-oxidants such as fish oil, vitamin E, and green-tea extract, but there is no strong 
evidence for the efficacy of these supplements (Bushby, 2010). 
3.1.5.2 Orthopedic Interventions 
Braces and orthoses are most helpful in prolonging ambulation in patients with DMD, 
which in turn results in a better outcome and reduced incidence of scoliosis (Hsu, 1993; Manzur, 
2009). Knee ankle foot orthoses (KAFOs) may prolong ambulation by as much as 18 months to 
2 years by assisting standing (Kinali, 2007; Manzur, 2009). Although KAFOs are not as effective 
as iliotibial band (ITB) surgical resection, progressive casting may be the best alternative in 
individuals for whom surgery is not a viable option (Do, 2002; Main, 2007).  
Surgical interventions are sometimes necessary for the orthopedic consequences of 
DMD. In the case of scoliosis, surgical spinal fusion is best tolerated when an individual still 
retains good respiratory function and has started a more rapid progression of the scoliosis (Van 
Opstal, 2011). Patients and their families are often satisfied with the results of spinal fusion, due 
to a more comfortable sitting posture, reduction in pain, and better quality of life (Takaso, 2010). 
Contractures can also be released surgically. This can include hip, knee, elbow, or ankle 
contractures. It is important to release contractures to maintain or regain upright positioning as 
well as slow the progression of scoliosis (Griffet, 2011). Studies have shown that while surgery 
can increase ankle dorsiflexion in the short term, contractures recur, and individuals who did not 
undergo surgery retained better functionality (Rose, 2010).  
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3.1.5.3 Rehabilitation Interventions 
Individuals with DMD are sensitive to contraction-induced muscle damage, so a balance 
must be maintained between muscle use and disuse (McDonald, 2002). Overall, low-intensity 
exercises are recommended while still ambulatory, and mobilizing passive or actively-assisted 
exercises are recommended for non-ambulatory patients (Jansen, 2010). Physical training and 
physiotherapy are especially effective in combination with corticosteroid use (Manzur, 2009; 
Jansen, 2010).  
3.1.5.4 Pulmonary Interventions 
Complications result from a progressively diminishing respiratory reserve, including 
sleep apnea and hypoxemic events (Manzur, 2009). Several interventions have recently been 
implemented, including non-invasive ventilation (NIV). NIV is able to correct hypoventilation 
during sleep and does not require tracheostomy. Cough-assist devices supplement lowered forced 
vital capacity (FVC) and the regular use of a cough-assist device is effective in decreasing the 
incidence of pulmonary complications such as pneumonia.  
3.1.5.5 Cardiac Interventions  
Because of improvements to the pulmonary management of individuals with DMD, the 
prevalence of DCM is becoming an increasing cause of mortality (Spurney, 2011). It is important 
to consider early preventative treatment for cardiac failure, which includes prophylactic ACE-
inhibitors and beta-blockers, although timing is still controversial (Manzur, 2009). Cardiac 
condition can be monitored through electrocardiogram (EKG), echocardiogram, cardiac MRI, 
CT imaging, and PET scans and assessment should be done annually until an abnormality is 
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found (Kaspar, 2009). Medication should be started by the earliest detection of DCM (Bushby, 
2010).  
3.1.5.6 GI/Nutrition/Swallowing Interventions 
Obesity is a common concern in ambulatory patients taking corticosteroids (Marigne, 
2011). It is important to regularly monitor weight gain and offer dietary advice in order to reduce 
the complications of obesity (Martigne, 2011). Conversely, in late nonambulatory patients, 
weight loss is a concern as difficulties with chewing, swallowing, or aspiration appear (Martigne, 
2011). Nutritional supplementation and eventual gastrostomy insertion are commonly used 
interventions for the cachexia that can accompany the late stages of DMD (Seguy, 2002).  
3.1.5.7 Psychological Interventions 
Because of the various psychosocial issues associated with DMD, it is important to 
consider psychological assessments at critical times, including at the time around diagnosis, 
before entering school, and after a change in function (Bushby, 2010). Assessments should 
include evaluation of emotional adjustment/coping, neurocognitive and neuropsychological 
function, and speech and language. Psychosocial wellbeing should be evaluated in the patient, 
siblings, and parents (Pangalila, 2011; Bushby, 2010). 
Several interventions for psychosocial support are available, and need to be 
individualized to the specific needs of the patient and family. Psychotherapy can involve parental 
management training when the child has externalizing behaviors such as aggression, or 
individual therapy for when the child has internalizing behaviors such as depression. Group 
therapy is available to improve social skills, as well as family therapy for difficulties in 
adjustment and coping, and applied behavior analysis for children with autism spectrum 
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disorders (Bushby, 2010). Medications can be prescribed for comorbidities such as ADHD and 
OCD, as well as for depression, anxiety, and emotional dysregulation (Bushby, 2010).  
There are also interventions and activities that convey psychological benefit outside of 
psychotherapy and pharmaceuticals. Increasing awareness of DMD among school personnel and 
peers, as well as an individualized education plan (IEP) can help maximize the child’s potential 
in school as well as minimize the activities that may pose a risk for complications (Bushby, 
2010.  
3.1.6 Emerging Therapeutics 
There are two main categories of emerging treatments for DMD that are currently being tested in 
clinical trials. The first is based on the premise of repairing or replacing the mutated dystrophin 
gene, and the second focuses on rescuing the translation of dystrophin (Partridge, 2011). The 
most promising method in this first category uses a single-stranded DNA virus (recombinant 
adeno-associated virus (AAV)) vector to provide a functional, yet truncated, copy of the 
dystrophin gene (Goyenvalle, 2011). The 14kb cDNA sequence of the dystrophin gene is too 
large for AAV vectors to carry, so minidystrophins and microdystrophins were designed that 
eliminated most of the central rod domain, expected to give a BMD-like dystrophin protein 
(Goyenvalle, 2012; Partridge, 2011). However, one drawback of AAV vector delivery is the 
potential for an immune response, which may require short-term immunosuppression during 
administration (Partridge, 2011).  
The most promising therapy for rescuing translation is exon-skipping using antisense 
oligonucleotides (AOs) (Nakamura, 2009; Partridge, 2011). These AOs are designed to bind to a 
specific region of mRNA post-transcription to alter splicing of the mRNA such that the mature 
 19 
transcript has an in-frame deletion, thus rescuing a dystrophin protein that retains both N- and C-
terminals (Fragall, 2011; Manzur, 2009). Depending on the dystrophin gene deletion location 
and its effect on reading frame, skipping an adjacent exon can restore the reading frame and 
potentially modify a DMD phenotype to enable a clinical course of a milder BMD phenotype 
(Nakamura, 2009; Aoki, 2010). Based on an analysis of the prevalence of specific deletions, 
skipping exon 51 would rescue the highest percentage of DMD deletions, and clinical trials 
testing exon 51 skipping strategies are currently showing promise (Lu, 2011; Brolin, 2011; 
Goemans, 2011). Drawbacks of exon-skipping include the requirement to design a different AO 
for the purpose of skipping each exon and the need for a constant supply of the AO in tissues 
producing dystrophin (Manzur, 2009). Delivery to relevant tissue is also an issue (Goyenvalle, 
2011). A recent innovation combines these two most promising therapies into one, by using 
AAV vectors to transport exon-skipping AOs to the muscle (Goyenvalle, 2011; Goyenvalle, 
2012).  
Other therapeutics still under development include the induced increase in utrophin 
expression to supplement deficient dystrophin activity and the read-through of premature 
truncation mutations (Ervasti, 2007; Goyenvalle, 2011). Utrophin is highly homologous to 
dystrophin, but is expressed most in fetal development and expression declines in the newborn 
period (Ervasti, 2007). It is hypothesized that an approximately seven-fold increase in utrophin 
expression could compensate for a complete lack of dystrophin (Ervasti, 2007; Goyenvalle, 
2011).  
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3.2 BECKER MUSCULAR DYSTROPHY 
Becker muscular dystrophy is a neuromuscular disease that resembles DMD, but is characterized 
by a slower progression and later onset. BMD and DMD are allelic disorders and there is a 
spectrum of severity (Engel, 2004). BMD is less common than DMD, and affects approximately 
1 in 17,500 male births (Emery, 1991). 
3.2.1 Clinical Features 
Individuals with BMD typically present with lower limb weakness and calf pain with exercise in 
the earliest stages (Bushby, 1993). The average age of symptom onset is 12 years old, but there is 
significant variability. Severity can range from a DMD-like presentation to mild weakness and 
exercise intolerance presenting in the 6th decade (Yazaki, 1999). Almost 90% of affected 
individuals are symptomatic by age 20 years (Bushby, 1993). 
The transition from ambulatory to non-ambulatory varies with clinical severity, but on 
average, individuals with BMD require a wheelchair for mobility in their 30’s (Becker, 1962; 
Norman, 1990). Cognitive impairment is sometimes present and is more severe in early-onset 
cases (Engel, 2004; Bushby, 1993). There may be a correlation between cognitive impairment 
and mutations that interrupt the dystrophin isoforms expressed in CNS tissue (Giliberto, 2004; 
Muntoni, 2003). BMD can also shorten the expected lifespan, with the average age of death at 42 
years old (Bradley, 1978; Emery, 1976).  
DCM and other cardiac manifestations are the most common source of morbidity and 
mortality, and do not correlate with severity of skeletal muscle involvement (Melacini, 1996; 
Darras, 2011). Indeed, because of the slower skeletal muscle progression and the ability to lead 
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an active lifestyle, cardiac symptoms are more apparent in individuals with BMD (Kaspar, 
2009). In milder forms of BMD, DCM can be the first presenting symptom (Engel, 2004). DCM 
in BMD stems from a similar pathway as DCM in DMD, although fibrosis begins in the right, 
rather than left ventricle (Kaspar, 2009).  
3.2.2 Diagnosis 
The diagnostic process for BMD is similar to that of DMD. The hallmark of BMD is a partial 
dystrophin deficiency (Engel, 2004; Mehler, 2000; Anthony, 2011). Although 90% of dystrophin 
mutations follow the ‘reading frame rule,’ molecular testing cannot always predict phenotype, 
and it is therefore important to combine molecular testing with clinical observation and/or 
measurement of dystrophin levels on muscle biopsy (Manzur, 2009).  
3.2.3 Genetics 
BMD and DMD are allelic disorders, and BMD is also caused by a deficiency in dystrophin. 
BMD is therefore also inherited in an X-linked manner, with the same recurrence risks as DMD. 
As with DMD, maternal gonadal mosaicism has been reported in families with BMD (Voit, 
1992), but it is difficult to estimate the prevalence. Men with BMD retain up to 70% of their 
fertility as compared to their unaffected brothers (Bushby, 1993). If an affected male has 
children, all daughters will be carriers of the dystrophin mutation, and no sons will inherit the 
mutation.  
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3.2.4 Management 
Management for BMD involves many of the same interventions as DMD, with some minor 
exceptions. In BMD, the primary source of mortality is heart failure due to DCM (Eagle, 2002; 
Kaspar, 2009). As in DMD, cardiac functioning should be monitored annually following 
diagnosis, and more often once an abnormality is identified (Finsterer, 2008; Kaspar, 2009). 
ACE-inhibitors and beta-blockers are available to slow the progression of DCM (Kaspar, 2009). 
Heart transplantation is also a viable option that has been successful, but individuals with BMD 
have an increased risk for anesthetic complications (Kaspar, 2009; Komanapalli, 2006). 
Treatment with glucocorticoids has not been studied in BMD and is not a routinely 
recommended therapy. 
3.3 SPINAL MUSCULAR ATROPHY 
The term “spinal muscular atrophy” (SMA) is used to describe a group of diseases characterized 
by the degeneration and eventual loss of cells in the spinal cord known as anterior horn cells 
(Engel, 2004; Wee, 2010). Most often, SMA refers to the most common disease in this group – 
proximal SMA – which is further subdivided into four types based on clinical severity, as 
described in detail below (Engel, 2004; Wee, 2010). The incidence of SMA is between 1 in 6000 
and 1 in 10,000 births (Su, 2011; Lorson, 2010; Pearn, 1978), making it the most common fatal 
autosomal recessive disorder (Prior, 2010).  
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3.3.1 Clinical Features 
SMA is a highly variable neuromuscular disease characterized by the degeneration of motor 
neurons in the spinal cord, resulting in progressive muscle weakness and paralysis (Prior, 2010).  
SMA is divided into four subtypes based on clinical severity. SMA type I is the most 
severe, with onset of symptoms in the first six months of life. Children with SMA type I are 
unable to sit unassisted, and are not expected to live longer than two years without respiratory 
support (Wee 2010; Engel, 2004). SMA type II typically will present with symptoms in the first 
year of life. While children with SMA type II can sit unassisted, they are unable to walk, and 
survival is variable (Wee 2010; Engel, 2004). People with SMA type III can walk without aid, 
and life span is not markedly reduced (Wee 2010; Engel, 2004). SMA type III is further divided 
into IIIa and IIIb, with age of onset before or after age 3, respectively (Engel, 2004). Adult SMA, 
or SMA type IV, has an age of onset after age 30 with variable severity (Engel, 2004).  
The severe muscle weakness in SMA causes a number of orthopedic consequences, 
including the formation of contractures, spinal deformity, osteopenia, and pain (D’Amico, 2011). 
Daily functions are limited by physical ability. Feeding difficulties are often present and may 
require gastrostomy. The most significant source of mortality, however, is from respiratory 
distress. Although the diaphragm is spared in SMA, expiratory and intercostal muscles are 
weakened, making breathing difficult (D’Amico, 2011). This leads to recurrent chest infections, 
decreased respiratory function, impaired cough with poor secretion clearance, and eventually 
respiratory failure (Wang, 2007; D’Amico, 2011).  
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3.3.2 Diagnosis 
There is no substrate or biomarker to aid in the diagnosis of SMA. Diagnosis relies on clinical 
observation and molecular genetic testing (Ogino, 2004; D’Amico, 2011). SMA should be on the 
list of differential diagnoses when a severely weak child or hypotonic baby presents with normal 
attentiveness and cognitive function (Menezes, 2011; D’Amico, 2011). SMA-related weakness is 
typically proximal and symmetrical, and tendon reflexes are diminished or absent (Wang, 2007; 
D’Amico, 2011). There are no associated sensory abnormalities (Wang, 2007). In SMA type I, 
there may be feeding difficulties, a weak cry and cough, and impaired head control (D’Amico, 
2011). Other diagnostic tests (including CK levels, electromyography (EMG), and nerve 
conduction studies) can help distinguish other neuromuscular diseases from SMA (Wang, 2007).  
3.3.3 Genetics 
SMA is inherited in an autosomal recessive pattern. It is estimated that the pan ethnic carrier 
frequency for SMA is between 1:25 and 1:66 (Hendrickson, 2009; Prior, 2010). All the subtypes 
of proximal SMA are caused by mutations in the survival motor neuron-1 (SMN1) gene 
(Lefebvre, 1995; Bürglen, 1996). The vast majority (95-98%) of cases are caused by 
homozygous deletion of SMN1, with a small minority of cases caused by a heterozygous whole 
gene deletion / point mutation combination, which does not allow the SMN protein to function 
(Bürglen, 1996).  
Although SMN1 is the gene that causes SMA, SMN2 is the most influential in 
determining prognosis, and therefore subtype. SMN1 and SMN2 are both located at 5q13; SMN1 
is distal to SMN2. SMN1 and SMN2 are highly homologous, and the coding sequence differs by 
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just one base pair in exon 7 (c.840C>T) (Prior, 2010). This silent nucleotide change does not 
alter the amino acid sequence, but affects splicing (D’Amico, 2011). It is thought that this silent 
change either disrupts an exonic splicing enhancer (ESE) or creates an exonic splicing silencer 
(ESS) (Kashima, 2003; Lorson, 2010). Although the exact mechanism is not known, SMN2 is 
known to primarily produce a quickly-degraded RNA product lacking exon 7, called SMN∆7, 
although some amount of functional SMN protein is also produced (Lorson, 2010). SMA 
prognosis is correlated with the amount of SMN protein preserved. With the loss of both copies 
of SMN1, prognosis is directly correlated with the number of SMN2 copies an affected person 
has.  
Copy number variation in SMN2 ranges from 0-3 in the general population, with 10-15% 
of unaffected individuals having no copies (Ogino, 2002; Gerard, 2000; Prior, 2010). People 
with SMA must have at least 1 copy of SMN2, but there is still variability. 1-2 copies of SMN2 is 
most often associated with SMA type I; people with SMA type II typically have 3 copies; and 
the majority of people with SMA type III have 3-4 copies (Gerard, 2000; Mailman, 2002; Prior, 
2010). This variability and overlap of SMN2 copy number between clinical presentations makes 
it difficult to predict prognosis based on SMN2 copy number alone (Wang, 2007).  
Pan ethnic carrier screening for SMA has been recommended by the American College of 
Medical Genetics (ACMG), but is limited by the need for gene dosage testing (Prior, 2010). 
Approximately 9% of the population has 3 copies of SMN1, and logically, a carrier could have 
two copies of SMN1 on one chromosome, and no copies on the other. Gene dosage testing is not 
able to distinguish between an SMA carrier 2/0 genotype and a non-carrier 1/1 genotype, and 
might therefore miss up to 9% of carriers for SMA (Prior, 2010).  
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3.3.4 Management 
Management for SMA has historically been focused on palliative care and supportive therapy, 
and there is no known cure. Recently, guidelines outlining standard of care in SMA were 
published (Wang, 2007). Care for individuals with SMA should be coordinated by a 
neuromuscular specialist and include care through pulmonology, gastroenterology, orthopedics, 
and palliative care (Wang, 2007; D’Amico, 2011). Ultimately, the interventions pursued should 
be considered in the context of goals for quality of life for the patient, often as determined by his 
or her parents and family.  
Pulmonary complications are the leading cause of mortality in the more severe types of 
SMA. This can include chest infections, respiratory failure, swallowing dysfunction, and reflux 
(D’Amico, 2011). Respiratory interventions include cough-assist devices, non-invasive 
ventilation (NIV), bi-level positive air pressure (BPAP), and eventually a tracheostomy 
(D’Amico, 2011). Other complications, such as feeding difficulties or obesity secondary to 
limited mobility, can be addressed through nutritional support and intervention, and a 
gastrostomy, if needed (Wang, 2007).  
Interventions for muscle weakness and the associated orthopedic consequences should 
encourage standing or walking based on an individual’s capability (Wang, 2007). Braces and 
splints can preserve range of motion while reducing pain (Wang, 2007). Supportive equipment, 
orthotics, and assistive technology should take into consideration the individual’s primary 
posture and maximum ability (Wang, 2007). Scoliosis correction should be approached 
cautiously, with consideration given to a patient’s respiratory function, as individuals with SMA 
have an increased risk for anesthetic complications (Wang, 2007; D’Amico 2011).  
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Palliative care plays an important part in the clinical management of SMA. Especially in 
more severe types of SMA, therapies to extend the lifespan may decrease the overall quality of 
life (Wang, 2007). Appropriate support for grieving family members, including bereavement 
support and hospice care, is available. End of life care decisions are ideally made after sufficient 
time has passed since the initial diagnosis, but before an emergent situation arises (Wang, 2007).    
3.4 NEWBORN SCREENING 
Newborn screening (NBS) is a public health initiative established in the 1960s that aims to 
identify infants at a higher risk for certain disorders, who would benefit from early diagnosis and 
management (CDC, 2004). Most disorders identified by NBS are not outwardly apparent at birth, 
but would cause death or permanent disability if left untreated (Wilson, 1968; CDC, 2004). For 
this reason, it is important to identify those infants that are at a higher likelihood of having these 
disorders and begin treatment immediately.  
As the name implies, NBS involves a screening test. By definition, NBS is not diagnostic, 
and many infants that screen positive will not have the disorder in question. These are known as 
“false positives.” Likewise, NBS may miss some infants that do in fact have a given disorder. 
These are known as “false negatives.” Ideally, a screening test would have very few false 
positives and no false negatives. False negatives lead to a delay in diagnosis for individuals that 
require treatment, causing harm. False positives increase the cost of a screening program, 
because all screen-positive infants undergo additional testing to determine those who have the 
disease in question.  
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3.4.1 Phenylketonuria 
The disease that first brought the need for population-wide screening to the public’s attention 
was phenylketonuria (PKU).  Patients with PKU lack phenylalanine hydroxylase (PAH), an 
enzyme that metabolizes phenylalanine into tyrosine (NIH, 2001; Blau, 2011). Phenylalanine is a 
common amino acid found in most protein-rich foods, such as milk, eggs, meat, and nuts. 
Without PAH, phenylalanine will accumulate and thus will be converted to phenylpyruvate, 
which can be detected in the urine (Blau, 2011). PKU, if left untreated, will lead to 
developmental delay, microcephaly, albinism, seizures, and mental retardation (Trefz, 2011). If 
phenylalanine intake is restricted through a modified diet started within weeks of birth and 
continued throughout adulthood, these disease characteristics can be avoided (NIH, 2001; Koch, 
2002).  
Dr. Robert Guthrie developed a test for PKU using only a drop of blood that was 
inexpensive, fast, and accurate (Bodamer, 2010). This became the first “newborn screen” used to 
screen all infants while still in the hospital, in order to start a modified diet as early as possible 
(Wilcken, 2008). Dried blood spots are still collected on Guthrie cards made of special filter 
paper (Bodamer, 2010).  
3.4.2 Wilson and Jungner Criteria 
After the development of a reliable population screen for PKU, screens for several other diseases 
were created (Bodamer, 2010). In 1968, the World Health Organization commissioned a book 
addressing the ethical principles and practices of screening newborns (Wilson and Jungner, 
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1968). Wilson and Jungner developed a set of guidelines that could be followed addressing 
whether a disease should or should not be included in a NBS program: 
1.   “The condition sought should be an important health problem. 
 
2.   There should be an accepted treatment for patients with recognized disease. 
 
3.   Facilities for diagnosis and treatment should be available. 
 
4.   There should be a recognizable latent or early symptomatic stage. 
 
5.   There should be a suitable test or examination. 
 
6.   The test should be acceptable to the population. 
 
7.   The natural history of the condition, including development from latent to declared 
disease, should be adequately understood. 
8.   There should be an agreed policy on whom to treat as patients. 
 
9.  The cost of case-finding (including diagnosis and treatment of patients diagnosed) 
should be economically balanced in relation to possible expenditure on medical 
care as a whole. 
10. Case-finding should be a continuing process and not a “once and for all” project.” 
(Wilson and Jungner, 1968) 
 
These criteria constitute the gold standard by which new potential NBS are judged. 
 
 
 
 
3.4.3 Technology 
 
 
 
 
Guthrie’s first PKU screen was a bacterial inhibition assay (Bodamer, 2010), but this has been 
replaced in many states by the development of tandem mass spectrometry (MS/MS), which can 
screen multiple samples for multiple diseases simultaneously (Naylor, 1999). Polymerase chain 
reaction (PCR) is used to screen for hemoglobinopathies (Jinks, 1989). A radioimmunoassay 
screens for congenital hypothyroidism through measurement of T4 levels (Sadler, 1978). 
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3.4.4 Mandatory vs. State-specific NBS 
Not all disorders are screened by NBS in every state. The American College of Medical Genetics 
recommends a core panel of 29 diseases, including 9 organic acidurias, 5 fatty-acid oxidation 
disorders, 6 amino acidurias, 3 hemoglobinopathies, and 6 other conditions (congenital 
hypothyroidism, congenital adrenal hyperplasia, biotinidase deficiency, classical galactosemia, 
cystic fibrosis, and hearing loss); almost all can be screened using MS/MS (Watson, 2006).  
3.5 HISTORY OF NBS FOR DMD/BMD/SMA 
3.5.1 NBS for DMD 
In the mid-1970s, it was demonstrated that a screening test for DMD could be performed on the 
dried blood spots already collected through the established NBS program (Zellweger, 1975).   
In newborns with DMD, CK activity levels are elevated (Zellweger, 1975). CK levels can 
also be elevated in other muscle conditions as well as for unrelated reasons, including muscle 
stress during birth. For this reason, testing newborn CK level detects all infants with DMD, but 
results in many false positive results (Drousiotou, 1998).  
There have been several trials of NBS for DMD, and it is currently offered for newborn 
boys with parental consent in some countries, including Wales, Canada, and Belgium (Bradley, 
1993; CDC, 2004). The German infant screening program recently ended in November 2011 
(correspondence with G. Scheuerbrandt, 7 Dec 2011). Each of these programs was unique in 
their approach to screening. Germany screened only boys at 4-6 weeks of life, starting in March 
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of 1977. This choice of when to screen reduced the rate of false positive results and encouraged 
autonomy in the decision to screen. The screen was voluntary, and required private payment of 
approximately $20 (Scheuerbrandt, 2011).  
There are currently 4 hospitals in the United States that offer optional NBS for DMD, 
through a CDC-funded research study conducted by investigators at the Columbus Children’s 
Research Institute in Ohio (Mendell, 2012). In the past, NBS was offered in other parts of the 
United States, including parts of Pennsylvania (Pittsburgh), New York, Oregon, Iowa, and 
Texas, as well as parts of Brazil, France, New Zealand, and Puerto Rico (CDC, 2004). 
3.5.2 NBS for SMA 
There have been no population-wide NBS programs for SMA, although there has been a research 
trial that identified and confirmed 4 positive results in 40,103 screened babies (Prior, 2010). 
Most commonly, NBS relies on substrate markers detected by MS/MS. DNA 
confirmation, when used, is primarily employed as a second-tier confirmation of first-tier-
positive results (Prior, 2010). However, there is no biochemical marker for SMA; thus, DNA 
would be required as the first-tier substrate (Prior, 2010). An approach such as direct DNA 
testing for first-tier testing may be practical in the future for NBS, so it is reasonable to look into 
the ethics of a population-wide screen for SMA.  
The carrier rate for SMA is estimated between 1:25 and 1:66, and SMA has an incidence 
between 1:6000 and 1:10,000 live births. In 2007, Pyatt et al. showed that it was possible to 
extract sufficient DNA from the standard NBS blood spots to effectively screen for SMA, with a 
sensitivity of 100% and a specificity of 99.5% (Pyatt, 2007). The sensitivity would be closer to 
 32 
95-98% after accounting for the small percentage of affected people who do not have 
homozygous SMN1 deletions (Prior, 2010).  
Treatment for SMA is currently palliative, but there are promising clinical trials ongoing 
and planned, including the rescue of the transcriptional product from SMN2. Similar to exon-
skipping in DMD, AOs would target SMN2 pre-mRNA to suppress exon 7 skipping (MacKenzie, 
2012). Rather than producing SMN∆7, functional SMN protein would be produced, and testing 
in mouse models has been promising (MacKenzie, 2012). NBS for SMA would allow enrollment 
in potential clinical trials as an infant. It is thought that in order to be most effective for the child, 
protein rescue must occur before damage to the anterior horn cells becomes irreversible. This 
requires clinical trial enrollment, and ultimately treatment, before symptoms present (Prior, 
2010).  
3.6 ETHICS OF NBS FOR DMD 
The consideration of population-based NBS for DMD/BMD/SMA can be controversial. The 
primary source of this controversy is the lack of evidence that early detection of 
DMD/BMD/SMA will lead to a better outcome for the child. Recent promising developments in 
therapy for DMD especially have increased interest in creating a practical pathway for adding 
DMD to the NBS program. When focusing on DMD, several key issues include who to screen, 
when to perform screening, and whether NBS for DMD should be offered as a voluntary, 
optional screen.  
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3.6.1 Who to Screen 
In consideration of the practicality of including DMD in the currently established NBS program, 
it is important to assess who should be offered screening. As an X-linked condition, DMD 
almost exclusively affects males, so it is potentially feasible to screen only male infants rather 
than both males and females.  
Screening only males would meet the Wilson and Junger screening goal of identifying 
infants that will become symptomatic and require treatment for their disease, recognizing that the 
occasional symptomatic female will be missed (Wilson and Jungner, 1968; Ross, 2006). This 
would allow the identification of the vast majority of infants that could be started on the current 
experimental therapies.  
Screening both males and females offers the added benefit of identifying carrier females, 
and subsequently at-risk families before an affected male is conceived. However, not every 
carrier female will be detected by NBS, and this may provide false reassurance to a family if a 
girl is screen negative (Ross, 2006). From an ethical standpoint, there is no precedent for carrier 
screening of infants, and this is a decision that could be delayed until adulthood, when the 
individual can decide for him- or herself whether the information is valuable (Hiraki, 2006; Ross, 
2002). The identification of a female carrier may also negatively impact the child’s self-esteem 
and her relationships with others (Ross, 2006).  
3.6.2 When to Screen 
There is ongoing discussion on when screening for DMD would be most beneficial: at birth, at a 
later well-child appointment, or when symptoms present. The current approach is symptomatic 
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diagnosis and treatment. There are many advantages to this approach, including the avoidance of 
insurance discrimination due to early disease identification. Additionally, symptomatic diagnosis 
is the responsibility of the individual, and therefore does not use public funding (Kemper, 2007). 
However, on average, approximately 2 years elapse from the time a parent first reports 
symptoms in an affected son until a diagnosis is made (Ross, 2006). In the past 20 years, efforts 
to increase pediatricians’ recognition of DMD have not shortened this diagnostic odyssey (Ross, 
2006).  
NBS is a well-established public health initiative with structures and resources in place 
for infants who have a positive NBS test. Therefore, it is appealing to include more diseases in 
this infrastructure rather than to fund screening at a later time. Screening in the newborn period 
may also improve the physician’s ability to treat DMD most effectively. Glucocorticoid 
treatment prolongs ambulation and improves quality of life, and the current recommendation is 
to begin corticosteroid treatment when boys with DMD have stopped gaining motor milestones, 
but before their motor skills have begun to decline (Mendell, 2012; Bushby, 2010). The average 
age of diagnosis for DMD is currently 5 years of age (Ciafaloni, 2009), but the loss of motor 
skills may have already begun before this age. An earlier diagnosis could lead to better medical 
management for the child (Mendell, 2012).  
Another advantage to screening in the newborn period is the time gained with the early 
diagnosis, to prepare both emotionally and by practical measures for the challenge and long-term 
nature of caring for a patient with DMD. Parsons et al. (2002) conducted a psychosocial study in 
Wales in which parents of infants with a positive NBS test for DMD and children diagnosed with 
DMD after the newborn period were surveyed. The authors concluded that the majority of 
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parents in both cohorts were in favor of the earlier diagnosis for the emotional and practical 
reasons mentioned above (Parsons, 2002).  
There are also potential disadvantages to including DMD as part of the already 
established NBS program. Past screening trials have shown a high rate of enrollment, which 
raises the concern that enrolled parents may not have made an autonomous decision to 
participate. It could also be potentially confusing to present the NBS for DMD as an optional 
screen, when other NBS programs are essentially mandatory (Kemper, 2007). Additionally, there 
is the possibility of lingering doubt over the accuracy of a false positive result (Parsons, 2002), 
which occurred in 2 out of 20 parents of the cohort that tested positive on the primary screen, but 
were then found to be negative on secondary screen. However, this occurred when informed 
consent for NBS for DMD had not been optimal (Parsons, 2002). Researchers have also cited the 
possibility of anxiety or impaired bonding with infants who are identified as affected with DMD 
through NBS (Bradley, 1993). Overall, Parsons found no evidence of rejection from either 
assessment by a health visitor or mothers’ responses to the rejection/protection index. There was 
also no difference in protectiveness during the first year of life (Parsons, 2002).  
Screening for DMD at a later well-child appointment such as a 6- or 12-month checkup 
provides an alternative to screening newborns prior to hospital discharge. Separating the timing 
of screening for DMD from the state-mandated NBS program helps separate the goal of 
screening for an untreatable condition (preparation) from the goal of screening for a treatable 
condition (prevention). This separation in timing is also better suited for a voluntary, opt-in 
screen (Ross, 2006). However, this would separate screening from the established infrastructure 
of the current NBS program (Ross, 2006). By 6-12 months of life, CK levels in carrier females 
have often normalized, so identification of carrier females is less sensitive beyond the newborn 
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period. Additionally, a population-wide screen performed later than the newborn period would 
be difficult, because not all children are seen reliably at well-child appointments. 
3.6.3 Opt-in vs. Opt-out 
Although the evidence is strong for the potential benefits of NBS for DMD, including a sensitive 
screen with almost no false negatives and minimal psychological harm, a compelling reason to 
include DMD in mandatory NBS remains a requirement. There is not yet a cure for DMD, and 
the benefits of early intervention are difficult to quantify. There is not a standardized treatment 
plan, and currently doctors and parents work together to make many decisions regarding 
treatments and the timing of treatments. The lack of a standardized and clearly beneficial 
treatment is the main reason why DMD does not meet the Wilson and Jungner screening criteria. 
For this reason, it is reasonable to consider a voluntary, opt-in NBS for DMD.  
In consideration of the ethical challenge presented by NBS for DMD, Ross states that 
“Overall, expanding NBS to DMD has potential benefits and risks and individual couples and 
families may decide differently on whether or not the benefit: risk ratio is positive… If one 
believes that it is reasonable for some parents to choose NBS for DMD and for other parents to 
refuse to test their children, then screening for DMD ought to be voluntary.”  
One of the most compelling arguments against an opt-in NBS for DMD while the baby is 
still in the hospital is that this is not the ideal time for a truly informed consent from the new 
parents. In Wales, there was an opt-in rate of 94% to screen for DMD (Parsons, 2002). Opt-in 
rates are highest when requests are done in person, and when testing can be performed 
immediately (Bekker, 1993; from Ross, 2006). 
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It is because of these ethical issues that we sought to assess parents’ opinions toward 
screening for DMD/BMD/SMA.  
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4.0  MATERIALS AND METHODS 
In order to achieve the specific aims, two cohorts were surveyed regarding their attitudes toward 
NBS for DMD/BMD/SMA. The Muscular Dystrophy Association (MDA) cohort consisted of 
parents of children with DMD, BMD, or SMA. The Magee cohort consisted of expectant parents 
with no regard to family history. This study was approved by the University of Pittsburgh 
Institutional Review Board.  
4.1 QUESTIONNAIRES 
Two questionnaires were used in this research study (Appendix A). The questionnaire distributed 
to the MDA cohort was created by Edwin Naylor, Ph.D. to assess the acceptability of adding 
DMD to the NBS panel (Naylor, 1992), and was modified only to include SMA. This 
questionnaire was also distributed at one other center (Medical University of South Carolina), 
and took approximately 5 minutes to complete. The questionnaire distributed to the Magee 
cohort was solely used at the University of Pittsburgh Medical Center (UPMC), and took 
approximately 10 minutes to complete. Data from the independent survey was extrapolated to fit 
the original multicenter survey.  
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4.2 RECRUITMENT  
All participation for this research study was voluntary, and there was no compensation for 
participants. Parents of children with DMD, BMD or SMA were identified and approached 
during routine MDA clinic visits at Children’s Hospital of Pittsburgh of UPMC or the adult 
neuromuscular clinic of UPMC. A scripted verbal consent (Appendix B.1) was read to every 
potential participant, and upon agreement, questionnaires were given to the parent(s) present. 
Additional surveys, along with a consent letter (Appendix B.1.1) were mailed to clinic families 
that were not seen in clinic during the recruitment period.   
Expectant parents were recruited at Magee Women’s Hospital of UPMC in Pittsburgh, 
PA. Potential participants were approached while waiting for hospital tours of the labor and 
delivery facilities at Magee Women’s Hospital. Tours are given to expectant couples during the 
2nd or 3rd trimester of pregnancy. A scripted verbal consent (Appendix B.2) was read to every 
potential participant, and upon agreement to participate in the study, questionnaires were given 
to expectant mothers and fathers. Questionnaires, but no identifying information from 
participants, were collected immediately upon completion. 
4.3 ANALYSIS 
All identifying information was removed from survey responses when relevant. Responses were 
then entered into two Excel spreadsheets. Chi-square values and corresponding p-values were 
calculated using the R-project statistical analysis program, an open-source computing language 
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available through http://cran.r-project.org/. For the purposes of this study, significance was 
determined by a p-value less than 0.05.  
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5.0  RESULTS 
5.1 MDA COHORT 
A total of 65 parents, including 48 mothers and 17 fathers, were surveyed at the time of data 
analysis. Of these 65 parents, 14 (21.5%) had one child, 19 (29.2%) had two children, 16 
(24.6%) had three children, and 16 (24.6%) had four or more children. Sixty-four parents 
reported their age range, of which 5 (7.8%) were between 20-29 years, 14 (21.9%) were between 
30-39 years, and 45 (70.3%) were 40 years or older.  
Of these 65 parents, 51 (78.5%) had a child with DMD, 9 (13.8%) had a child with BMD, 
and 5 (7.7%) had a child with SMA. Sixty-four parents reported if there was a prior family 
history of DMD/BMD/SMA, as shown in Table 1.  
 
Table 1: Prior family history in the MDA cohort, stratified by disease. 
 DMD BMD SMA Total 
Family history 7 1 1 9 (14.1%) 
No family history 43 8 4 55 (85.9%) 
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5.1.1 Specific Aim 1 
The first specific aim was to assess how parents of children with DMD, BMD or SMA feel about 
adding DMD/BMD/SMA to the NBS program. 
Overall, we found strong support for NBS among parents of children with DMD, BMD, 
or SMA. Thirty-seven out of 65 parents (57.0%) believed that DMD, BMD, and SMA should be 
included in the mandatory NBS, and another 26 parents (40.0%) believed screening should be 
offered to parents and performed after consent was given (Table 2). Therefore, the total level of 
support from parents of children with DMD, BMD, or SMA without any advances in treatment is 
97.0%.  
 
Table 2: MDA parents' opinions on NBS for DMD/BMD/SMA. 
Newborn babies should be screened for 
muscular dystrophy and spinal muscular 
atrophy: 
Number (Percentage) 
“Yes, as a routine procedure” 37 (57.0%) 
“Yes, but only if treatable” 1 (1.5%) 
“Yes, but only with parent consent” 26 (40.0%) 
“No” 1 (1.5%) 
 
 This trend of parental support for NBS is further supported by the number of parents who 
would have future children screened at birth for DMD/BMD/SMA (Figure 3). Sixty-three out of 
65 parents responded to this question. Of these, 54 (85.7%) said they would want future children 
screened, 3 (4.8%) would not want future children screened, and 6 (9.5%) were not sure.  
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Figure 3: Support for NBS among parents of children with DMD/BMD/SMA.  
Parents responded to the question, “Would you want future children screened for muscular 
dystrophy and spinal muscular atrophy?” with responses, “Yes,” “No,” and “Not sure.”  
 
This support does not significantly change with the child’s diagnosis (p=0.157), the 
presence of a family history of DMD/BMD/SMA (p=0.389), parent’s age (p=0.294), or number 
of children (p=0.448), as calculated by Fisher’s exact test (Figures 4, 5, 6, and 7).  
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Figure 4: Parental support for NBS stratified by child's diagnosis.  
Parents responded to the question, “Would you want future children screened for muscular 
dystrophy and spinal muscular atrophy?” with responses, “Yes,” “No,” and “Not sure.” DMD=Duchenne 
muscular dystrophy, BMD=Becker muscular dystrophy, SMA=spinal muscular atrophy. 
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Figure 5: Parental support for NBS stratified by the presence or absence of a family history.  
Parents responded to the question, “Would you want future children screened for muscular 
dystrophy and spinal muscular atrophy?” with responses, “Yes,” “No,” and “Not sure.” 
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Figure 6: Parental support for NBS stratified by parental age.  
Parents responded to the question, “Would you want future children screened for muscular 
dystrophy and spinal muscular atrophy?” with responses, “Yes,” “No,” and “Not sure.” 
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Figure 7: Parental support for NBS stratified by the number of children a parent has.  
Parents responded to the question, “Would you want future children screened for muscular 
dystrophy and spinal muscular atrophy?” with responses, “Yes,” “No,” and “Not sure.”  
5.1.2 Additional Comments 
Parents were given the option of leaving additional comments after filling out the survey. Some 
highlighted comments are included in Table 3: 
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Table 3: Selected comments from parents of children with DMD, BMD, or SMA. 
Comment Parent 
“We needed to put [our child] through 1 year of unnecessary testing: 
MRI x2, blood test, etc. when a simple blood test could have 
given us an answer much sooner.” 
D-15, mother of 2.5 
year-old with SMA. 
“If treatments become available in [the] future, then absolutely [there] 
should be pre-screening.” 
D-28, mother of 10 
year-old with DMD. 
“Screening should be done only if there is a family history of the 
disease.” 
D-31, father of 26 year-
old with BMD. 
“An early diagnosis may have hindered his progress as we strived to 
"catch up" to developmental milestones. A diagnosis may have 
kept us from pushing as hard.” 
D-61, mother of 23 
year-old with DMD. 
“[Screening is] very important because of other situations that may 
happen and need surgery… at birth or before diagnosis.” 
D-64, mother of 10 
year-old with DMD. 
“More information tends to be better than less but since our child was 
adopted I would hope that additional screening wouldn't decrease 
the number of children being matched with families.” 
D-11, adoptive mother 
of 17 year-old with 
DMD. 
“I think it would have been easier on us as parents to know what was 
wrong early on.” 
D-9, mother of 5 year-
old with DMD. 
 
5.2 MAGEE COHORT 
A total of 400 expectant parents were surveyed at the time of data analysis. Three-hundred eighty 
participants identified a gender, including 212 expectant mothers and 168 expectant fathers. Of 
the 400 participants, 5 (1.3%) were less than 20 years old, 154 (38.5%) were between 20-29 
years old, 218 (54.5%) were between 30-39 years old, 21 (5.3%) were between 40-49 years old, 
and 2 (0.5%) were 50 years or older. Three-hundred ninety eight participants self-identified their 
racial background; 351 (88.2%) identified as White or Caucasian, 19 (4.8%) identified as Black 
or African-American, 27 (6.8%) identified as Asian, none identified as Native Hawaiian or Other 
Pacific Islander, and 1 (0.3%) identified as American Indian or Alaska Native. Out of 351 
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participants that self-identified an ethnicity, 11 (3.1%) identified as Hispanic or Latino. Of the 
400 participants, 325 (81.3%) were expecting to be first-time parents.  
On a scale from 1-7, with 1 meaning conservative and 7 meaning liberal, we asked 
participants to self-identify their economic views, social/political values, and spiritual views. As 
a whole, respondents self-reported to be moderate, with an average of 3.77 for economic views, 
4.16 for social/political values, and 4.08 for spiritual views.  
Three hundred ninety nine participants indicated if they personally knew anyone with 
muscular dystrophy; 75 (18.8%) did. Three hundred ninety eight participants indicated if they 
personally knew anyone with a genetic diagnosis; 144 (36.2%) did. Three hundred ninety three 
participants indicated if they knew of anyone (such as a celebrity, athlete, or politician) with a 
genetic diagnosis; 169 (43.0%) did.  
5.2.1 Specific Aim 2 
The second specific aim was to assess how expectant parents feel about adding 
DMD/BMD/SMA to the NBS program. 
To analyze how expectant parents feel about NBS for DMD/BMD/SMA, we first 
analyzed how they felt about NBS in general. This was done through their overall awareness of 
the NBS program, as well as through directed questions about whether they felt screening babies 
for genetic diseases was necessary or wrong. Overall, expectant parents were not aware of the 
NBS program (37.6% awareness), as shown in Figure 8. Parents who already had children were 
more likely to be aware than first-time parents, but this was not found to be statistically 
significant using Fisher’s exact test (p=0.1833) (Figure 9).  
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Figure 8: Awareness of NBS in expectant parents.  
Expectant parents responded to the question, “Are you aware that all newborns are screened for 
over 20 treatable genetic diseases through the Pennsylvania Newborn Screening Program before they leave 
the hospital?” with responses, “Yes,” or “No.” 
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Figure 9: Awareness of NBS in expectant parents with and without prior children.  
Expectant parents responded to the question, “Are you aware that all newborns are screened for 
over 20 treatable genetic diseases through the Pennsylvania Newborn Screening Program before they leave 
the hospital?” with responses, “Yes,” or “No.” 
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We next asked if they felt that screening babies for genetic diseases was necessary. 
Overall, parents did not feel strongly that NBS was necessary, as shown in Figure 10. Fifty-three 
percent either agreed or agreed completely with the statement, “Screening babies for genetic 
diseases is necessary.” Thirty-eight percent neither agreed nor disagreed. Nine percent either 
disagreed or disagreed completely.  
 
 
Figure 10: Expectant parents’ opinions on the necessity of screening for genetic diseases.  
Expectant parents responded to the statement, “Screening babies for genetic diseases is necessary.” 
on a 5-point scale, where 1, 3, and 5 were defined as, “Disagree Completely,” “Neither Agree nor Disagree,” 
and “Agree Completely,” respectively.  
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We next asked if screening babies for genetic diseases was wrong. Overall, parents felt 
strongly that it was not wrong, as shown in Figure 11. Eighty-eight percent either disagreed or 
disagreed completely with the statement, “Screening babies for genetic diseases is wrong.” One 
percent agreed, no parents agreed completely, and 11% neither agreed nor disagreed. 
 
 
Figure 11: Expectant parents’ opinions on whether screening for genetic disease is wrong.  
Expectant parents responded to the statement, “Screening babies for genetic diseases is wrong.” on a 
5-point scale, where 1, 3, and 5 were defined as, “Disagree Completely,” “Neither Agree nor Disagree,” and 
“Agree Completely,” respectively. 
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After evaluating overall opinions of NBS, we considered whether parents wanted to 
know if their child had an incurable disease that would shorten his/her lifespan. 
DMD/BMD/SMA fit this model of disease. When asked, “If there were a disease without a cure 
that would affect your child’s health and shorten his/her lifespan, would you want to know at 
birth?” 92.5% of parents said yes, as shown in Figure 12.  
 
 
Figure 12: Support for NBS among expectant parents.  
Expectant parents were asked, “If there were a disease without a cure that would affect your child’s 
health and shorten his/her lifespan, would you want to know at birth?” with responses, “Yes,” or “No.” This 
presents a general model for which DMD/BMD/SMA are specific examples. 
 
The proportion of expectant parents who would choose to screen their child did not 
change with personal knowledge of a person with muscular dystrophy (p=0.9697), personal 
knowledge of a person with a genetic diagnosis (p=0.994), or knowledge of a person (such as a 
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celebrity, athlete, or politician) with a genetic diagnosis (p=0.1745), calculated using Fisher’s 
exact test (Figures 13, 14, and 15).  
 
 
Figure 13: Support for NBS among expectant parents with and without personal knowledge of a 
person with muscular dystrophy.  
Expectant parents were asked, “If there were a disease without a cure that would affect your child’s 
health and shorten his/her lifespan, would you want to know at birth?” with responses, “Yes,” or “No.” 
MD=muscular dystrophy 
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Figure 14: Support for NBS among expectant parents with and without personal knowledge of a 
person with a genetic disease.  
Expectant parents were asked, “If there were a disease without a cure that would affect your child’s 
health and shorten his/her lifespan, would you want to know at birth?” with responses, “Yes,” or “No.”  
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Figure 15: Support for NBS among expectant parents with and without knowledge of a person (such 
as a celebrity, athlete, or politician) with a genetic disease.  
Expectant parents were asked, “If there were a disease without a cure that would affect your child’s 
health and shorten his/her lifespan, would you want to know at birth?” with responses, “Yes,” or “No.” 
5.2.2 Specific Aim 3 
The third specific aim was to assess what factors influence expectant parents’ feelings about 
NBS for DMD/BMD/SMA. 
We divided the survey questions into 6 factor categories: bonding, anxiety, decision 
regret, time to prepare, family planning, and early diagnosis. Expectant parents were then asked 
to rank these 6 factors by which was most influential in their opinions about NBS for 
DMD/BMD/SMA. 348 parents responded, 205 (59%) of which answered that an early diagnosis 
was the most influential factor, as shown in Figure 16. Seventy-seven (22%) felt that time to 
prepare for the disease was the most influential factor.  
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Figure 16: Factors that play a primary role in expectant parents' opinions of NBS for 
DMD/BMD/SMA.  
*A=Anxiety, B=Bonding, E=Early diagnosis, F=Family planning, R=Decision regret, T=Time to 
prepare. 
 
When the influencing factors of the expectant parents who would choose to screen their 
child were separated from the expectant parents who would choose not to screen their child, the 
most influential factor remains early diagnosis in both groups; however, anxiety was the second 
most influential factor for parents who would choose not to screen their child, as shown in Table 
4 and Figure 17. Bonding and time to prepare both received equal rankings as the third most 
influential factors for parents who would choose not to have their child screened.  
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Table 4: The most influential factors for expectant parents who would screen their child, compared 
to the most influential factors for expectant parents who would not screen their child. 
 Would you have your child screened at birth 
for an incurable, life-shortening disease? 
Yes No 
What factor is most 
influential? 
Anxiety 22 (6.8%) 7(28%) 
Bonding 12 (3.7%) 3 (12%) 
Early diagnosis 196 (60.7%) 9 (36%) 
Family planning 13 (4%) 2 (8%) 
Decision regret 6 (1.9%) 1 (4%) 
Time to prepare 74 (22.9%) 3 (12%) 
 
 
Figure 17: Factors that play a primary role in expectant parents’ opinions of NBS for 
DMD/BMD/SMA, stratified by whether an expectant parent would choose to screen his/her child. 
*A=Anxiety, B=Bonding, E=Early diagnosis, F=Family planning, R=Decision regret, T=Time to 
prepare. 
 
To determine expectant parents’ consistency in their answers, we asked a number of 
inverse question pairs regarding influential factors. Participants were asked to indicate on a scale 
from 1-5 their feelings about a statement, with 1 meaning, “disagree completely,” 5 meaning, 
“agree completely,” and 3 meaning, “neither agree nor disagree.” Concordance was calculated as 
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the number of expectant parents that responded equally and oppositely between a question and 
its inverse. Of the expectant parents that were surveyed, 67.3% were consistent regarding their 
opinions on bonding, 44.5% were consistent regarding their opinions on anxiety, and 36.8% 
were consistent regarding their opinions on time to prepare, as shown in Table 5. 
 
Table 5: Concordance rates in paired questions.  
Expectant parents responded to each statement on a 5-point scale, where 1, 3, and 5 were defined as, 
“Disagree Completely,” “Neither Agree nor Disagree,” and “Agree Completely,” respectively.  
Category Question Average 
response 
Number of 
concordant pairs (%) 
Anxiety “Screening would increase my anxiety level.” 3.20 178/400 (44.5%) 
“Screening would decrease my anxiety level.” 2.79 
Bonding “Screening would affect how I bond with my 
child.” 
1.81 269/400 (67.3%) 
“Screening would not affect how I bond with my 
child.” 
3.88 
Time “Screening would allow me to enjoy the time 
with my child before he/she shows symptoms, if 
my child’s results were abnormal.” 
3.48 147/400 (36.8%) 
“Screening would take away the first few happy 
years with my child, if my child’s results were 
abnormal.” 
1.80 
Early 
diagnosis 
“Screening would allow doctors to make a 
diagnosis sooner.” 
4.36 N/A 
Family 
planning 
“Screening would affect my decision to have 
more children.” 
2.38 N/A 
Decision 
regret 
“I would be sorry that I decided to have my baby 
screened, if my child’s results were abnormal.” 
1.60 N/A 
 
5.2.3 Additional comments 
Expectant parents were given the option of leaving additional comments after filling out the 
survey. Highlighted comments are included in Table 6. 
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Table 6: Selected comments from expectant parents. 
Comment Participant 
“The concern that I would have for screening for these illnesses is that 
there is no cure for [them]. Often children that have these illnesses 
present very early. The test would need to have a very high 
specificity or parents may be put through an incredible degree of 
anxiety over the possibility of a false positive test.” 
C-30, expectant father 
with family history 
of MD. 
“So much research shows potential benefits for early diagnosis of many 
conditions that I feel we should screen for everything possible to 
give the best potential outcomes for our child.” 
C-100, expectant 
mother. 
“I am in favor of screening. An abnormal result would allow us to 
prepare and also I would be more likely to try and have my child 
experience as many activities/events/places as possible before they 
lose any physical ability. I would also begin a more aggressive 
savings plan for future costs associated with treatments and my 
child's life.” 
C-121, gender 
unspecified. 
“I believe screening is up to the parents if they choose and for me I'd 
want to be sure my child would not be put in any pain to be tested!” 
C-163, expectant 
father. 
“Like with most things, I believe screening is a choice parents should 
have the option to make.” 
C-241, expectant 
father with family 
history of MD. 
“Really #3-6 [anxiety, family planning, bonding, regret] are not an 
influence at all.” 
C-264, expectant 
father with family 
history of MD. 
“Screening would not negatively impact my bond with my children -
regardless of the results. I would raise them and love them 
unconditionally. I believe it would help me prepare for the future 
and allow me an opportunity to research the conditions to get the 
best care possible for my children.” 
C-282, expectant 
mother with family 
history of MD. 
“I would prefer to not know for the first month. But I would not delay 
interminably. All these tests are too overwhelming the first day or 
two. They should happen month 2.” 
C-328, gender 
unspecified. 
“While I find screenings stressful, the benefits outweigh the risk, 
especially if you are already screening for 20 other conditions.” 
C-371, expectant 
father. 
“My husband and I feel very strongly that genetic testing - for us - 
would only be used if it helped us to prepare differently (or our 
doctors).” 
C-385, expectant 
mother. 
“I am a big believer in knowing as much as possible as soon as 
possible. Ignorance is NOT bliss!” 
C-389, expectant 
mother. 
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5.3 HOW DO THE MDA AND MAGEE COHORTS COMPARE? 
5.3.1 Specific Aim 4 
Our fourth specific aim was to compare parental support in the two cohorts.  
Overall, both cohorts supported NBS for DMD, BMD, and SMA. All 65 parents 
surveyed from the MDA cohort answered the question “Should newborns be screened for 
DMD/BMD/SMA?” as discussed above. Without further developments in treatment, 97% of 
parents supported NBS. Three-hundred ninety nine expectant parents answered the question “If 
there were a disease without a cure that would affect your child’s health and shorten his/her 
lifespan, would you want to know at birth?” as discussed above. A total of 92.5% of participants 
supported NBS. Although a higher percentage of the MDA cohort supported NBS, it was not 
statistically significant based on Fisher’s exact test (p=.295), as shown in Table 7.  
 
Table 7: Comparison of NBS support in MDA and Magee cohorts.  
NBS=Newborn screening, MDA=Muscular Dystrophy Association. 
Support NBS? Yes (%) No (%) Total 
MDA 63 (97%) 2 (3%) 65 
Magee 369 (92.5%) 30 (7.5%) 399 
Total 432 32 464 
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6.0  DISCUSSION 
6.1 MDA COHORT 
Supportive of our hypothesis, parents of children with DMD/BMD/SMA strongly supported 
NBS for these conditions. Ninety-seven percent felt that NBS should be implemented, even 
without further therapeutic advances; however, only 85.7% would want their next child screened. 
This difference can be explained by the strong minority of parents (40.0%) who felt that NBS for 
DMD/BMD/SMA should only be implemented with parental consent. It is reasonable to 
speculate that some parents who support optional NBS would choose not to have their own child 
screened.  
In consideration of the broader implications of the opinions expressed through the survey 
responses, if parents who have already had an affected child, express a desire to not have their 
next child screened, then it seems reasonable to avoid implementing a mandatory screen for the 
general population. This means that the remaining options should include an opt-in screen at 
birth, an opt-out screen at birth, and an optional screen offered at a later time.  
Our data is in accordance with previous studies done on parental opinions of NBS for 
DMD. Parsons et al. retrospectively evaluated parents’ opinions on NBS for DMD after having a 
child screen positive during the implementation of NBS for DMD in Wales (Parsons, 2002). 
They found that 85-89% of parents supported NBS, whether the result was found to be a false 
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positive or their child received a diagnosis of DMD. Another study surveyed parents of children 
with DMD who were diagnosed symptomatically and found that 90% of those who responded 
were in favor of NBS (Firth, 1983).  
Qualitatively, parents’ comments echo a number of alternatives to a universal NBS that 
have been mentioned in past discussions of NBS for DMD/BMD/SMA. One parent mentioned 
that screening should occur if and when there is a treatment developed; this, along with evidence 
that early intervention for DMD provides a better outcome than symptomatic diagnosis and 
treatment, would mean DMD would meet the original Wilson and Jungner screening criteria. 
Another parent brought up screening when there is a family history of one of these diseases. 
Parents also brought up several influential factors assessed in the second part of this study: the 
benefits and drawbacks of early diagnosis, and the benefits of time for both family and medical 
staff to prepare for the child’s medical needs. 
6.2 MAGEE COHORT 
Consistent with our hypothesis, expectant parents supported NBS for DMD/BMD/SMA, as 
demonstrated by the 92.5% of parents who would want to know at birth if their child had a life-
shortening, incurable genetic disorder. This was considered a model for DMD/BMD/SMA for 
several reasons. DMD/BMD/SMA currently do not have a cure, and convey varying degrees of 
disability throughout the lifespan. We anticipated a low level of background knowledge of 
DMD/BMD/SMA and their associated complexities in the general population. By asking about 
parents’ feelings before describing each disease, we can confidently say that this high level of 
support is applicable to many diseases that fit the above descriptors. Additionally, by asking 
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about parents’ opinions on screening for an incurable disorder, we can conclude that our 
respondents support NBS for DMD/BMD/SMA without further therapeutic development.  
We expected that the most influential factor on parents’ opinions of NBS would be time 
to prepare, both emotionally and practically. Although several comments reflected the 
importance of preparing for the child’s diagnosis, the majority of parents responded that an early 
diagnosis was the most influential factor. Both early diagnosis and time to prepare are closely 
related concepts, and ranked first and second in the list of influential factors in parents who 
would choose to screen their child.  
Our data supports previous studies done on parental opinions of NBS for DMD with no 
selection for family history. One study divided NBS into 3 categories: treatable (PKU), less 
treatable (CF), and untreatable (DMD) (Plass, 2010). Parental support was 73.3% for the 
inclusion of untreatable diseases into mandatory NBS. Smith et al. evaluated mothers’ opinions 
on NBS for DMD and found that 94% felt that screening was acceptable despite the lack of an 
available treatment (Smith, 1990). Other studies have qualitatively evaluated parents’ opinions of 
NBS for DMD. Campbell and Ross used focus groups to compare parental opinions of NBS for 
PKU and DMD; although parents were strongly supportive of NBS for PKU, many psychosocial 
concerns were brought up regarding NBS for DMD (Campbell, 2003).  
Additional comments from expectant parents also gave a unique perspective into the 
thought processes that influenced parents’ opinions. Several parents expressed that screening 
should be a choice for parents. Other parents outlined thoughtful reasons both for screening and 
for not screening. Parents who supported screening listed emotional, medical, and financial 
preparation for the child. Parents who did not support screening cited both the anxiety of false 
positive results, and the acceptability of a symptomatic diagnosis.   
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6.3 LIMITATIONS 
One major limitation in our ability to compare the two cohorts was the distribution of two 
different questionnaires. Although some data can be interpreted between both cohorts, it would 
be interesting to see how the influencing factors compared between expectant parents, and 
parents of children with DMD, BMD, or SMA.  
In the MDA questionnaire, parents were asked to respond to the statement, “Newborn 
babies should be screened for muscular dystrophy and spinal muscular atrophy,” with one of the 
following responses: “Yes, as a routine procedure,” “Yes, but only if treatable,” “Yes, but only 
with parental permission,” “No,” or “Not sure.” A limitation of this question is that parents were 
not allowed to choose more than one response. For example, it is possible that some parents felt 
that screening should be mandatory, if treatment becomes available. This question would force 
parents to choose which response is most important, and may lead to an underestimation of the 
importance of therapeutic development to parents of children with DMD, BMD, or SMA when 
considering NBS for DMD/BMD/SMA.  
After analyzing the data, there was a lower than anticipated awareness of the current NBS 
program in the Magee cohort. Several expectant parents expressed in their comments that their 
opinions of screening would depend on how invasive the screen was, or if screening would hurt 
the child. This confusion could have been avoided by including a paragraph about the current 
NBS procedures, and that screening for DMD/BMD/SMA should not require any additional 
blood. The invasiveness of a screen could potentially have a large impact on whether a parent 
considers the screen acceptable or not.  
When assessing the most influential factors in expectant parents’ opinions of NBS, the 
terms “early diagnosis” and “time to prepare” may have been difficult to separate from one 
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another. In past studies, “early diagnosis” has been used as a term to describe the avoidance of a 
diagnostic odyssey, or a reduction in time between when a parent first notices the child’s 
symptoms and an eventual diagnosis. Naturally, an early diagnosis gives the family (and doctors) 
time to prepare, and thus may have confounded parent’s ranking.  
It is interesting to note that the majority of expectant parents who identified a well-known 
figure with a genetic disease named someone with a multifactorial disease, such as Parkinson’s 
disease or amyotrophic lateral sclerosis (ALS). Although only a small fraction of these 2 
conditions are due to single-gene defects, there is a genetic component to each, and the phrasing 
of the question does not exclude them.  
When naming a well-known figure with a genetic disease, popular answers included 
Michael J. Fox, Ryan Clark (Pittsburgh Steeler), Stephen Hawking, Muhammad Ali, Chris Burke 
(actor from Life Goes On), and Lauren Potter (actress from Glee). However, this data may have 
been skewed by concurrent news events. Early in data collection, a Pittsburgh football player 
(Ryan Clark) was not allowed to play in an important game in Denver, Colorado, because 
doctors were concerned that his sickle cell anemia trait would cause him to have a blood crisis in 
Denver’s high altitudes. This news event coincided with an observed influx of respondents 
naming Ryan Clark as a celebrity with a genetic disease.   
6.4 IMPLICATIONS FOR RE-IMPLEMENTING OPT-IN, OR INITIATING OPT-
OUT NBS FOR DMD 
The lack of a proven improvement in long-term outcome that could be afforded by early 
identification and treatment of DMD, BMD, and SMA is a deterrent for their inclusion in the 
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established mandatory NBS. Although current exon-skipping clinical trials for DMD are 
promising, there is no evidence yet that a greater benefit will be reaped if treatment is started pre-
symptomatically, rather than upon symptomatic diagnosis. This also applies to current SMA 
clinical trials, although these trials are limited in their ability to demonstrate the benefits of pre-
symptomatic treatment without enrolling participants through NBS. Without such evidence, the 
majority of benefit for the inclusion of DMD, BMD, and SMA in NBS is most relevant to the 
parents, not the child. As such, parental choice should be considered a higher priority than in 
current NBS practice, which centers on the child’s right to a healthy life.  
When considering parental choice in NBS, there are two options: an opt-in program, 
where parents must consent for their child to be screened, and an opt-out program, where parents 
must be aware of the implications of the screen and actively disagree in order for their child not 
to be screened. Given the high majority of support for NBS for DMD/BMD/SMA in both 
cohorts, an opt-out screen may be more practical. Those who are aware of the screen and do not 
wish to know such information may make their wishes known, and those who are not aware of 
the screen are statistically likely to want to know. Ideally, all parents would be made aware of 
such a screen, but currently, the majority of expectant parents are not aware of the mandatory 
NBS panel, making the likelihood of awareness for an optional screen low. An opt-in screen 
would give the most autonomy to the parents, but would limit the general utility of NBS for these 
conditions.  
With an opt-in screen, informed consent becomes another key issue. Previous data has 
shown a high opt-in rate when the decision is made in the hospital shortly after birth (Bradley, 
1993). As discussed above, the environment right after the birth of a child is not necessarily the 
best time for an autonomous, informed consent. Additionally, if an opt-in screen were to be done 
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before parents leave the hospital, hospital time and resources would need to be allocated for 
informed consent. Such resources have a cost and are not always available. Opt-in rates have 
been shown to drop dramatically when parents are asked about screening even one month after 
the birth of a child (Scheuerbrandt, 1986; Scheuerbrandt, 2009); however, the interpretation of 
this finding is complex. 
For SMA, the young age of diagnosis and early onset of irreversible symptoms suggest 
consideration of an opt-out screen. Early enrollment in a clinical trial could have a direct benefit 
for the child’s overall health, thus elevating benefit to the child above parental choice. However, 
current knowledge and resources to predict prognosis of SMA based on SMN2 copy number are 
limited, and are not sufficient to predict which affected children will require early intervention. 
Ethically, a nebulous benefit to the child is not compelling evidence to override parental 
consideration. 
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7.0  CONCLUSION 
There is considerable current interest within families affected by muscular dystrophy and 
medical teams who care for them for the inclusion of DMD in the NBS panel. This interest is 
significantly supported by the promising gene therapy approaches for DMD treatment currently 
in clinical trials. The field is encouraged by the real potential for effective treatments for DMD to 
emerge from ongoing clinical research. None-the-less, this study provides strong support for the 
implementation of NBS for DMD/BMD/SMA without any further medical developments.  
Our specific aims in this study were to assess how expectant parents and parents of 
children with DMD/BMD/SMA felt about adding DMD/BMD/SMA to the NBS program, to 
assess what factors influence these opinions, and to compare the opinions of expectant parents 
with the opinions of parents of children with DMD/BMD/SMA. We have evaluated parents’ 
attitudes toward the inclusion of DMD/BMD/SMA in the standard NBS panel. Although there is 
strong support for screening, timing and importance of specific informed consent remain 
controversial. A majority of parents of children with DMD, BMD, or SMA supported mandatory 
screening, but a strong minority felt that screening should only be done with parental permission. 
Expectant parents supported screening for incurable, life-shortening diseases, such as 
DMD/BMD/SMA. The most influential factor in expectant parents’ opinions was the benefit of 
an early diagnosis. Both expectant parents and parents of children with DMD, BMD, or SMA 
supported screening, but support was not significantly higher in either cohort.  
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This study demonstrates that the addition of diseases that were not previously screened to 
the standard NBS program invokes the need to consider the beneficence of screening for these 
diseases in the context of parental opinions. Although there is currently no direct medical benefit 
of early diagnosis in DMD/BMD/SMA, parents responded that early diagnosis could have other, 
less tangible benefits. These benefits would be preserved in a voluntary screening program, and 
an optional screen after the newborn period would allow parents the most autonomy in their 
decision. 
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APPENDIX A 
QUESTIONNAIRES 
A.1 QUESTIONNAIRE FOR EXPECTANT PARENTS OR PARENTS OF NORMAL 
NEWBORNS 
 73 
Parental Attitudes Toward Newborn Screening for DMD/BMD/SMA 
 
THE FOLLOWING QUESTIONS ARE ABOUT YOU: 
 
Gender: a. Female b. Male 
 
Age (years):      Education: 
 a. less than 20     a. Some high school 
    b. 20-29     b. High school graduate 
 c. 30-39     c. Some college 
 d. 40-49     d. College graduate 
 e. 50+      d. Master's degree 
      e. Doctoral degree 
Race:       f. Other _________________ 
a. White or Caucasian 
b. Black or African-American   Marital Status: 
c. Asian      a. Married 
d. Native Hawaiian/Other Pacific Islander  b. Single 
 e. American Indian or Alaska Native   c. Divorced 
      d. Separated 
Ethnicity:      e. Not Married 
 a. Hispanic/Latino 
 b. Non-Hispanic 
 
How do you consider your economic views: 
Conservative      1----------2----------3----------4----------5----------6----------7  Liberal 
 
How do you consider your social/political values: 
Conservative      1----------2----------3----------4----------5----------6----------7  Liberal 
 
How do you consider your spiritual views: 
Conservative      1----------2----------3----------4----------5----------6----------7  Liberal 
 
What number child is this for you?  
a. 1st 
b. 2nd 
c. 3rd 
d. 4th 
e. 5th +  
 
Do you personally know anyone with muscular dystrophy?  
a. Yes 
b. No 
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Do you personally know anyone with a genetic disease, such as cystic fibrosis, sickle-cell 
anemia, or Down syndrome?  
a. Yes  Diagnosis: _____________________________________________ 
b. No 
 
Do you know of a person (for example, a celebrity, athlete, or politician) with a genetic disease?  
a. Yes  Person: _______________________________________________ 
b. No 
 
Are you aware that all newborns are screened for over 20 treatable genetic diseases through 
the Pennsylvania Newborn Screening Program before they leave the hospital? 
a. Yes 
b. No 
 
If there were a disease without a cure that would affect your child’s health and shorten his/her 
lifespan, would you want to know at birth?   
a. Yes 
b. No 
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Duchenne muscular dystrophy (DMD) is a genetic disease that causes muscle weakness 
beginning in the upper legs and arms. The muscles grow weaker as the child ages. DMD affects 
only boys, and these boys begin to show symptoms between ages 3-5 years. Most boys with 
DMD need wheelchairs by age 12, and their lifespans are much shorter than a person without 
DMD. Treatment of DMD includes physical therapy, medications, and special medical care for 
heart and lung problems. There is no cure for DMD. 
 
Becker muscular dystrophy (BMD) is another genetic disease that is caused by changes in the 
same gene as DMD. There is similar muscle weakness, but the weakness does not happen as 
quickly. BMD also affects only boys, but they begin to show symptoms at a later age. Lifespan is 
often shortened, but usually not as much as DMD. Treatment is similar to treatment of DMD. 
There is no cure for BMD.   
 
Spinal muscular atrophy (SMA) is a genetic disease with a wide range of symptoms. Over time, 
muscles of people with SMA get smaller and weaker due to poor communication between the 
spinal cord and the muscles. This weakness can be very mild, or it can be very severe. Age of 
onset ranges from early infancy to adulthood. There is no cure for SMA.  
 
 
 
 
We do not currently screen newborns for any of the above (DMD, BMD or SMA). We may soon 
have good screening tests for these but no cure to treat them. The following questions will help 
us decide how parents feel about screening newborns for these conditions. 
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Please indicate how each factor influences your opinion of newborn screening for DMD, BMD, 
and SMA by circling a number, 1-5, with 1 meaning, “disagree completely,” and 5 meaning, 
“agree completely.” 
 
            Disagree       Neither Agree              Agree 
              Completely        Nor Disagree           Completely 
1  2  3  4  5 
 
 
1. Screening would affect how I bond with my child: 
 
1-------------2-------------3-------------4-------------5 
 
2. Screening would increase my anxiety level: 
 
1-------------2-------------3-------------4-------------5 
 
3. Screening would affect my decision to have more children: 
 
1-------------2-------------3-------------4-------------5 
 
4. Screening babies for genetic diseases is wrong: 
 
1-------------2-------------3-------------4-------------5 
 
5. I would be sorry that I decided to have my baby screened, if my child’s results were 
abnormal: 
 
1-------------2-------------3-------------4-------------5 
 
6. Screening would allow me to enjoy the time with my child before he/she shows symptoms, if 
my child’s results were abnormal: 
 
1-------------2-------------3-------------4-------------5 
 
7. Screening would affect how I raise my child: 
 
1-------------2-------------3-------------4-------------5 
 
8. Screening would not affect how I bond with my child: 
 
1-------------2-------------3-------------4-------------5 
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            Disagree       Neither Agree              Agree 
       Completely        Nor Disagree           Completely 
1  2  3  4  5 
 
 
9. Screening would take away the first few happy years with my child, if my child’s results were 
abnormal: 
 
1-------------2-------------3-------------4-------------5 
 
10. Screening would decrease my anxiety level: 
 
1-------------2-------------3-------------4-------------5 
 
11. Screening would allow me to prepare emotionally for my child’s disease, if my child’s results 
were abnormal: 
 
1-------------2-------------3-------------4-------------5 
 
12. Screening babies for genetic diseases is necessary: 
 
1-------------2-------------3-------------4-------------5 
 
13. Screening would allow doctors to make a diagnosis sooner: 
 
1-------------2-------------3-------------4-------------5 
 
 
14. Please rank the following factors based on how much they influence your opinion on 
newborn screening, with 1 being the most influential and 6 being the least influential: 
 
Anxiety    _____ 
Bonding    _____ 
Decision to have more children  _____ 
Early diagnosis   _____ 
Time to prepare   _____ 
Potential for regret   _____ 
 
 
Additional comments:           
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A.2 QUESTIONNAIRE FOR PARENTS OF CHILDREN WITH D/BMD OR SMA 
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QUESTIONNAIRE FOR PARENTS OF CHILDREN WITH MUSCULAR 
DYSTROPHY OR SPINAL MUSCULAR ATROPHY  
 
=============================================================== 
 
THE FOLLOWING QUESTIONS ARE ABOUT YOU 
 
Relationship:   
 
 ___ Father  
 ___ Mother 
 ___ Other  
 
Age (years):      Education (highest level): 
  
 ____less than 20    ____8th Grade 
    ____20-29     ____12th Grade 
 ____30-39     ____College 
 ____over 40     ____Master's Degree 
       ____Doctoral Degree 
       ____Other 
 
Number of Children:    Religion: 
  
 ____One     ____Jewish 
 ____Two     ____Catholic 
 ____Three     ____Protestant 
 ____Four or more    ____Other 
 
Race or Ethnicity:    Marital Status: 
  
 ____White     ____Married 
 ____Black     ____Single 
 ____Asian     ____Divorced 
 ____Hispanic     ____Separated 
 ____Other     ____Not Married 
 
=============================================================== 
THE FOLLOWING QUESTIONS ARE ABOUT YOUR CHILD 
 
Child’s diagnosis: 
  
 ____Duchenne Muscular Dystrophy 
 ____Becker Muscular Dystrophy 
 ____Spinal Muscular Atrophy 
 ____Other Muscular Dystrophy (LGMD, congenital), specify: ______________ 
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Age of child when the diagnosis of muscular dystrophy or spinal muscular atrophy was 
confirmed: 
  
 ____Less than 4 weeks 
 ____1-6 months 
 ____Older than 6 months 
 
Age at which YOU first suspected something might be wrong: 
  
 ____Less than 1 month 
 ____1-12 months 
 ____1-5 years 
 ____5-10 years 
 ____Older than 10 years 
 
Current age of child: _____________ 
 
Who informed you about the diagnosis of your child? 
  
 ____Pediatrician 
 ____Obstetrician 
 ____Family doctor 
 ____Pediatric Neurologist/Neurologist 
 ____Physician at MDA Clinic 
 ____Other 
 
Are there other members of your family with muscular dystrophy or spinal muscular atrophy? 
 ____Yes If Yes, How many?__________________________________ 
 ____No Brothers or sisters___________ Other relative_____________ 
 
Was your child screened for muscular dystrophy or spinal muscular atrophy at birth? 
 ____Yes 
 ____No 
 ____Don't know  
 
=============================================================== 
 
PLEASE ANSWER THE FOLLOWING QUESTIONS REGARDING MUSCULAR 
DYSTROPHY, SPINAL MUSCULAR ATROPHY, AND NEWBORN SCREENING TO THE 
BEST OF YOUR KNOWLEDGE 
 
(1) Newborn screening for muscular dystrophy and spinal muscular atrophy is: 
 a) currently performed nationwide in the United States 
 b) offered by a small number of hospitals in the United States 
 c) not in use at all at the present time 
 d) not sure 
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PLEASE ANSWER THE FOLLOWING QUESTIONS REGARDING MUSCULAR 
DYSTROPHY, SPINAL MUSCULAR ATROPHY, AND NEWBORN SCREENING TO THE 
BEST OF YOUR KNOWLEDGE 
 
(2) Newborn babies should be screened for inherited disorders through state mandated newborn 
screening programs: 
 a) Yes, as a routine procedure 
 b) Yes, but only if treatable 
 c) Yes, but only with parental consent 
 d) No 
 e) Not sure 
 
(3) Newborn babies should be screened for muscular dystrophy and spinal muscular atrophy: 
 a) Yes, as a routine procedure 
 b) Yes, but only if treatable 
 c) Yes, but only with parental permission 
 d) No 
 e) Not sure 
 
(4) If your child was not detected through newborn screening, would you have wanted your child 
to have been screened for muscular dystrophy or spinal muscular atrophy: 
 a) Yes 
 b) No 
 c) Not sure 
 
(5) If your child was screened as a newborn, are you glad that was child was screened for 
muscular dystrophy or spinal muscular atrophy: 
 a) Yes 
 b) No 
 c) Not sure 
 
(6) Would you want future children screened for muscular dystrophy and spinal muscular 
atrophy: 
 a) Yes 
 b) No 
 c) Not sure 
 
Comments: 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
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APPENDIX B 
SCRIPTS 
B.1 SCRIPT FOR MDA CLINICS 
The purpose of this research study is to evaluate current attitudes towards newborn screening for 
Spinal Muscular Atrophy (SMA) and Duchenne/Becker Muscular Dystrophy (D/BMD). For that 
reason, we will be surveying parents of newborns and parents of children with these muscle 
conditions and asking them to complete a brief questionnaire. The questionnaire will take 
approximately 5 minutes to complete. If you are willing to participate, our questionnaire will ask 
basic demographic information such as age, race, years of education, religion; your feelings 
about newborn screening, and your experience with your child’s diagnosis. The risks associated 
with participating in this survey are minimal, and there are no direct benefits to you. This is an 
entirely anonymous questionnaire, and so your responses will not be identifiable in any way. All 
responses are confidential. Your participation is voluntary. This study is being conducted by Dr. 
Abdel-Hamid, who is a pediatric neuromuscular specialist. 
B.1.1 Parent Letter for MDA Clinic 
Dear Parent of ________, 
 
We are writing to you regarding a new research study being conducted by the Muscular 
Dystrophy Association (MDA) clinics at the University of Pittsburgh Medical Center (UPMC). It 
is a questionnaire-based study that will evaluate current attitudes toward newborn screening for 
Duchenne/Becker muscular dystrophy (D/BMD) and spinal muscular atrophy (SMA). We are 
approaching both expectant parents and parents of children with these muscle conditions and 
asking them to complete a brief questionnaire (enclosed).  
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If you are willing to participate, the questionnaire will take approximately 5 minutes to complete. 
It will ask basic demographic information, your feelings toward newborn screening, and your 
experience with your child’s diagnosis. This is an entirely anonymous questionnaire, and all 
identifying information will be removed prior to data entry. Your responses are confidential, and 
your participation is voluntary.  
 
The risks associated with filling out the questionnaire are expected to be minimal, and there are 
no direct benefits to you. However, your responses will be important for future discussions about 
newborn screening for D/BMD and SMA.  
 
To participate, please fill out the enclosed questionnaire and return it in the enclosed addressed 
envelope. By mailing the questionnaire, you are consenting to participate in this research study. 
If you have any questions about this research study, please contact Kate Hughes at the phone 
number below. Thank you for your consideration! 
 
Sincerely, 
Molly Wood, B.A.    Hoda Abdel-Hamid, M.D. 
Genetic Counseling Intern   Pediatric Neurologist 
University of Pittsburgh ’12   Children’s Hospital of Pittsburgh of UPMC 
 
Kate Hughes, M.S., C.G.C. 
Genetic Counselor, Clinical Research Coordinator 
University of Pittsburgh 
###-###-####. 
B.2 SCRIPT FOR EXPECTANT PARENTS 
 
The purpose of this research study is to evaluate current attitudes towards newborn screening for 
Spinal Muscular Atrophy (SMA) and Duchenne/Becker Muscular Dystrophy (D/BMD). All 
three diseases have onset of symptoms in childhood with varying degrees of muscle weakness, 
and convey a shortened lifespan. For that reason, we will be surveying expectant parents and/or 
parents of newborns and asking them to complete a brief questionnaire. The questionnaire will 
take approximately 10 minutes to complete. If you are willing to participate, our questionnaire 
will ask basic demographic information such as: age, race, years of education, religion; as well as 
your feelings about newborn screening. There are no foreseeable risks associated with this study, 
nor are there any direct benefits to you. This is an entirely anonymous questionnaire, and so your 
responses will not be identifiable in any way. All responses are confidential. Your participation 
is voluntary. This study is being conducted by Molly Wood, a genetic counseling intern, who can 
be reached at (###) ###-####.  
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IRB APPROVALS 
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